Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis
X Liu, Y Lang, Q Chai, Y Lin, Y Liao… - Frontiers in Pharmacology, 2022 - frontiersin.org
Purpose: According to the IMvigor130 trial, adding atezolizumab to platinum-based
chemotherapy was effective in the treatment of metastatic urothelial cancer (mUC). Based on …
chemotherapy was effective in the treatment of metastatic urothelial cancer (mUC). Based on …
Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost–effectiveness analysis
PF Zhang, F Wen, QJ Wu, Q Li - Journal of Comparative …, 2022 - becarispublishing.com
Purpose: To evaluate the cost–effectiveness of atezolizumab plus chemotherapy as first-line
treatment for metastatic urothelial cancer (mUC). Materials & methods: A Markov model was …
treatment for metastatic urothelial cancer (mUC). Materials & methods: A Markov model was …
Cost-effectiveness of atezolizumab plus chemotherapy as first-line therapy for metastatic urothelial cancer
S Qin, L Yi, S Li, C Tan, X Zeng, L Wang, Y Peng… - Advances in …, 2021 - Springer
Abstract Introduction The IMvigor130 trial found that atezolizumab plus platinum-based
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …
chemotherapy (atezolizumab group) as first-line therapy prolonged progression-free survival …
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Background Atezolizumab can induce sustained responses in metastatic urothelial
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab …
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences
D Tural, ÖF Ölmez, AT Sümbül, M Artaç, N Özhan… - European urology …, 2021 - Elsevier
Background Atezolizumab (ATZ) has demonstrated antitumor activity and manageable
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
safety in previous studies in patients with locally advanced or metastatic platinum-resistant …
[HTML][HTML] Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
Background Conventional criteria for tumor progression may not fully reflect the clinical
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …
benefit of immunotherapy or appropriately guide treatment decisions. The phase II …
Atezolizumab in metastatic urothelial carcinoma outside clinical trials: focus on efficacy, safety, and response to subsequent therapies
Background Little is known about the outcomes, safety, and response to subsequent
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …
therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab …
Real-world evidence from a single UK cancer center for atezolizumab in second-line setting in advanced urothelial cancer: Moving beyond clinical trials.
SA Hussain, M Qureshi, B Tahir, A Rehan, JWF Catto - 2022 - ascopubs.org
461 Background: Atezolizumab is approved for use in advanced urothelial cancer in second
line setting after platinum based chemotherapy. We conducted a retrospective study to …
line setting after platinum based chemotherapy. We conducted a retrospective study to …
Comparative effectiveness of non-cisplatin first-line therapies for metastatic urothelial carcinoma: phase 2 IMvigor210 study versus US patients treated in the Veterans …
N Vander Velde, A Guerin, R Ionescu-Ittu, S Shi… - European Urology …, 2019 - Elsevier
Background First-line treatments for cisplatin-ineligible patients with metastatic urothelial
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
carcinoma (mUC) include carboplatin-based chemotherapy and checkpoint inhibitors such …
[HTML][HTML] Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based …
Standard-of-care first-line treatment for metastatic urothelial carcinoma (mUC) is platinum-
based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients …
based chemotherapy (CTx). Maintenance immunotherapy is a treatment option for patients …